دورية أكاديمية
Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma.
| العنوان: | Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma. |
|---|---|
| المؤلفون: | Vaarwerk B; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Department of Paediatric Oncology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands., Breunis WB; Department of Paediatric Oncology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.; Department of Oncology and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland., Haveman LM; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Department of Paediatric Oncology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands., de Keizer B; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Jehanno N; Department of Nuclear Medicine, Institut Curie, Paris, France., Borgwardt L; Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen University Hospital, Copenhagen , Denmark., van Rijn RR; Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands., van den Berg H; Department of Paediatric Oncology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands., Cohen JF; Obstetrical, Perinatal and Pediatric Epidemiology Research Team (EPOPé), Centre of Research in Epidemiology and Statistics (CRESS), UMR1153, Université de Paris, Paris, France.; Department of General Pediatrics and Pediatric Infectious Diseases, Necker - Enfants malades hospital, Assistance Publique - Hôpitaux de Paris, Paris Descartes University, Paris, France., van Dalen EC; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Merks JH; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Department of Paediatric Oncology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands. |
| المصدر: | The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2021 Nov 09; Vol. 11. Cochrane AN: CD012325. Date of Electronic Publication: 2021 Nov 09. |
| نوع المنشور: | Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review; Systematic Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley Country of Publication: England NLM ID: 100909747 Publication Model: Electronic Cited Medium: Internet ISSN: 1469-493X (Electronic) Linking ISSN: 13616137 NLM ISO Abbreviation: Cochrane Database Syst Rev Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2004- : Chichester, West Sussex, England : Wiley Original Publication: Oxford, U.K. ; Vista, CA : Update Software, |
| مواضيع طبية MeSH: | Fluorodeoxyglucose F18* , Rhabdomyosarcoma*/diagnostic imaging, Cross-Sectional Studies ; Humans ; Lung ; Lymphatic Metastasis ; Neoplasm Staging ; Positron Emission Tomography Computed Tomography ; Positron-Emission Tomography ; Prospective Studies ; Radiopharmaceuticals ; Retrospective Studies ; Sensitivity and Specificity ; Tomography, X-Ray Computed |
| مستخلص: | Background: Rhabdomyosarcoma (RMS) is the most common paediatric soft-tissue sarcoma and can emerge throughout the whole body. For patients with newly diagnosed RMS, prognosis for survival depends on multiple factors such as histology, tumour site, and extent of the disease. Patients with metastatic disease at diagnosis have impaired prognosis compared to those with localised disease. Appropriate staging at diagnosis therefore plays an important role in choosing the right treatment regimen for an individual patient. Fluorine-18-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET) is a functional molecular imaging technique that uses the increased glycolysis of cancer cells to visualise both structural information and metabolic activity. 18 F-FDG-PET combined with computed tomography (CT) could help to accurately stage the extent of disease in patients with newly diagnosed RMS. In this review we aimed to evaluate whether 18 F-FDG-PET could replace other imaging modalities for the staging of distant metastases in RMS. Objectives: To determine the diagnostic accuracy of 18 F-FDG-PET/CT imaging for the detection of bone, lung, and lymph node metastases in RMS patients at first diagnosis. Search Methods: We searched MEDLINE in PubMed (from 1966 to 23 December 2020) and Embase in Ovid (from 1980 to 23 December 2020) for potentially relevant studies. We also checked the reference lists of relevant studies and review articles; scanned conference proceedings; and contacted the authors of included studies and other experts in the field of RMS for information about any ongoing or unpublished studies. We did not impose any language restrictions. Selection Criteria: We included cross-sectional studies involving patients with newly diagnosed proven RMS, either prospective or retrospective, if they reported the diagnostic accuracy of 18 F-FDG-PET/CT in diagnosing lymph node involvement or bone metastases or lung metastases or a combination of these metastases. We included studies that compared the results of the 18 F-FDG-PET/CT imaging with those of histology or with evaluation by a multidisciplinary tumour board as reference standard. Data Collection and Analysis: Two review authors independently performed study selection, data extraction, and methodological quality assessement according to Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2). We analysed data for the three outcomes (nodal involvement and lung and bone metastases) separately. We used data from the 2 × 2 tables (consisting of true positives, false positives, true negatives, and false negatives) to calculate sensitivity and specificity in each study and corresponding 95% confidence intervals. We did not consider a formal meta-analysis to be relevant because of the small number of studies and substantial heterogeneity between studies. Main Results: Two studies met our inclusion criteria. The diagnostic accuracy of 18 F-FDG-PET/CT was reported in both studies, which included a total of 36 participants. We considered both studies to be at high risk of bias for the domain reference standard. We considered one study to be at high risk of bias for the domain index test and flow and timing. Sensitivity and specificity of 18 F-FDG-PET/CT for the detection of bone metastases was 100% in both studies (95% confidence interval (CI) for sensitivity was 29% to 100% in study one and 40% to 100% in study two; 95% CI for specificity was 83% to 100% in study one and 66% to 100% in study two). The reported sensitivity of 18 F-FDG-PET/CT for the detection of lung metastases was not calculated since only two participants in study two showed lung metastases, of which one was detected by 18 F-FDG-PET/CT. Reported specificity was 96% in study one (95% CI 78% to 100%) and 100% (95% CI 72% to 100%) in study two. The reported sensitivity for the detection of nodal involvement was 100% (95% CI 63% to 100% in study one and 40% to 100% in study two); the reported specificity was 100% (95% CI 78% to 100%) in study one and 89% (95% CI 52% to 100%) in study two. Authors' Conclusions: The diagnostic accuracy of 18 F-FDG-PET/CT for the detection of bone, lung, and lymph node metastases was reported in only two studies including a total of only 36 participants with newly diagnosed RMS. Because of the small number of studies (and participants), there is currently insufficient evidence to reliably determine the diagnostic accuracy of 18 F-FDG-PET/CT in the detection of distant metastases. Larger series evaluating the diagnostic accuracy of 18 F-FDG-PET/CT for the detection of metastases in patients with RMS are necessary. (Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.) |
| References: | Clin Nucl Med. 2009 Mar;34(3):146-50. (PMID: 19352275) Ann Intern Med. 2011 Oct 18;155(8):529-36. (PMID: 22007046) Am J Nucl Med Mol Imaging. 2014 Mar 20;4(2):202-12. (PMID: 24753986) J Clin Oncol. 2006 Aug 20;24(24):3844-51. (PMID: 16921036) Lancet Oncol. 2014 Jan;15(1):35-47. (PMID: 24314616) AJR Am J Roentgenol. 2005 Apr;184(4):1293-304. (PMID: 15788613) Acad Emerg Med. 2013 Nov;20(11):1194-206. (PMID: 24238322) Pediatr Radiol. 2020 Feb;50(2):252-260. (PMID: 31628508) Pediatr Blood Cancer. 2010 Feb;54(2):222-7. (PMID: 19890901) Expert Rev Anticancer Ther. 2010 May;10(5):755-68. (PMID: 20470007) Handchir Mikrochir Plast Chir. 2004 Oct;36(5):296-300. (PMID: 15503260) Nat Rev Cancer. 2002 Sep;2(9):683-93. (PMID: 12209157) Eur J Nucl Med Mol Imaging. 2009 Dec;36(12):1944-51. (PMID: 19593561) Radiology. 2007 Dec;245(3):839-47. (PMID: 18024454) J Clin Oncol. 2011 Apr 1;29(10):1312-8. (PMID: 21357783) Cancer. 1995 Jan 1;75(1 Suppl):395-405. (PMID: 8001010) Pediatr Radiol. 2008 Sep;38(9):953-62. (PMID: 18636251) Medicine (Baltimore). 2015 Jul;94(28):e1142. (PMID: 26181552) Arch Dis Child. 2003 Apr;88(4):354-7. (PMID: 12651771) Radiology. 2010 Oct;257(1):158-66. (PMID: 20851940) CA Cancer J Clin. 2014 Mar-Apr;64(2):83-103. (PMID: 24488779) Turk J Pediatr. 2020;62(2):182-190. (PMID: 32419409) Anticancer Res. 2018 Jun;38(6):3635-3639. (PMID: 29848720) Cancers (Basel). 2014 Sep 29;6(4):1821-89. (PMID: 25268160) BMC Med Res Methodol. 2014 May 23;14:70. (PMID: 24884381) J Clin Oncol. 2007 Dec 1;25(34):5435-41. (PMID: 18048826) Clin Nucl Med. 2006 Dec;31(12):754-60. (PMID: 17117068) Ann Nucl Med. 2008 Aug;22(7):603-9. (PMID: 18756363) Cancer. 2017 Jan 1;123(1):155-160. (PMID: 27563842) Nucl Med Commun. 2006 Oct;27(10):795-802. (PMID: 16969262) J Clin Oncol. 2009 Nov 1;27(31):5182-8. (PMID: 19770373) Q J Nucl Med Mol Imaging. 2017 Dec;61(4):438-446. (PMID: 25996974) J Pediatr Surg. 2008 Dec;43(12):2186-92. (PMID: 19040932) J Pediatr Hematol Oncol. 2012 Mar;34(2):131-6. (PMID: 22134608) Clin Nucl Med. 2011 Aug;36(8):672-7. (PMID: 21716019) Clin Sarcoma Res. 2018 Apr 09;8:9. (PMID: 30116519) PET Clin. 2016 Jul;11(3):285-96. (PMID: 27321032) Eur Radiol. 2014 May;24(5):1153-65. (PMID: 24563179) Expert Rev Anticancer Ther. 2011 Feb;11(2):195-204. (PMID: 21342039) Pediatr Radiol. 2009 Jun;39 Suppl 3:482-90. (PMID: 19440769) Expert Rev Anticancer Ther. 2010 Aug;10(8):1285-301. (PMID: 20735314) J Clin Oncol. 2001 Jun 15;19(12):3091-102. (PMID: 11408506) Eur J Nucl Med Mol Imaging. 2009 Jan;36(1):23-36. (PMID: 18719909) Rev Med Chil. 2012 Sep;140(9):1116-25. (PMID: 23354632) Lancet Oncol. 2018 Aug;19(8):1061-1071. (PMID: 29941280) Sarcoma. 2001;5(1):9-15. (PMID: 18521303) J Pediatr Hematol Oncol. 2007 Jan;29(1):9-14. (PMID: 17230060) BMC Cancer. 2014 Sep 05;14:654. (PMID: 25189734) Front Med (Lausanne). 2020 Jul 14;7:281. (PMID: 32766257) AJR Am J Roentgenol. 2015 Apr;204(4):W384-92. (PMID: 25794087) Pediatr Blood Cancer. 2013 Jul;60(7):1128-34. (PMID: 23255260) J Clin Med. 2020 Aug 06;9(8):. (PMID: 32781683) J Natl Cancer Inst. 2019 Mar 1;111(3):256-263. (PMID: 30020493) Eur J Nucl Med Mol Imaging. 2012 Sep;39(9):1416-24. (PMID: 22699526) Methods Mol Biol. 2011;727:191-203. (PMID: 21331935) AJR Am J Roentgenol. 2001 Jul;177(1):229-36. (PMID: 11418435) Pediatr Blood Cancer. 2018 Feb;65(2):. (PMID: 28901637) Orthop Clin North Am. 2015 Jul;46(3):409-15, xi. (PMID: 26043054) J Nucl Med. 2011 Oct;52(10):1535-40. (PMID: 21903740) PET Clin. 2015 Jul;10(3):375-93. (PMID: 26099673) Eur J Nucl Med Mol Imaging. 2007 May;34(5):630-637. (PMID: 17048034) J Clin Oncol. 2013 Sep 10;31(26):3226-32. (PMID: 23940218) Am Soc Clin Oncol Educ Book. 2013;:415-9. (PMID: 23714563) Cochrane Database Syst Rev. 2021 Nov 9;11:CD012325. (PMID: 34753195) Pediatr Blood Cancer. 2007 Dec;49(7):901-5. (PMID: 17252575) Ann Nucl Med. 2009 Feb;23(2):155-61. (PMID: 19225939) Pediatr Blood Cancer. 2019 Mar;66(3):e27532. (PMID: 30393936) Nucl Med Commun. 2012 Oct;33(10):1089-95. (PMID: 22929116) J Clin Oncol. 2008 May 10;26(14):2384-9. (PMID: 18467730) J Clin Oncol. 2007 Feb 1;25(4):362-9. (PMID: 17264331) |
| المشرفين على المادة: | 0 (Radiopharmaceuticals) 0Z5B2CJX4D (Fluorodeoxyglucose F18) |
| تواريخ الأحداث: | Date Created: 20211109 Date Completed: 20211206 Latest Revision: 20240313 |
| رمز التحديث: | 20240313 |
| مُعرف محوري في PubMed: | PMC8577863 |
| DOI: | 10.1002/14651858.CD012325.pub2 |
| PMID: | 34753195 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1469-493X |
|---|---|
| DOI: | 10.1002/14651858.CD012325.pub2 |